{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:55:13Z","timestamp":1789048513801,"version":"build-2803163510"},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To investigate the effects of treatment with rosuvastatin and atorvastatin on serum endothelin-1 (ET-1) and asymmetrical dimethylarginine (ADMA) in elderly patients with coronary artery disease combined with hyperlipidemia. The data of 216 elderly patients with coronary artery disease combined with hyperlipidemia received during January 2023\u2013December 2023 were retrospectively analyzed. Based on the different treatment programs, they were divided into atorvastatin group (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0108) and rosuvastatin group (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a0108), and then before treatment, after 30d, 60d, 90d and 120d the two groups of patients were compared with the indicators of vascular endothelial function, immune function, blood lipid level, and adverse reactions. Comparison of the indicators of vascular endothelial function, immune function, and lipid level between the two groups of patients before treatment,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&gt;\u00a00.05. After 30d and 60d of treatment, the level of ET-1, ADMA, and visceral adipose tissue-derived serine protease inhibitor (Vaspin) was lower in the rosuvastatin group than in the atorvastatin group,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.05. Immune functions such as cluster of differentiation 4 positive (CD4+)\/cluster of differentiation 3 positive (CD3+)\/CD4+ and cluster of differentiation 8 positive (CD8+) ratios and other immune functions were higher than those in the atorvastatin group,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.05. Patients in the rosuvastatin group had lower lipid levels such as total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) than those in the atorvastatin group,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.05. The incidence of adverse reactions such as loss of appetite, headache, dizziness, fatigue, constipation, etc. in patients in the rosuvastatin group was lower than that in the atorvastatin group,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.05. Rosuvastatin compares favorably with atorvastatin in improving vascular endothelial function, improving immune function, lowering lipid levels, and mitigating adverse effects in elderly patients with coronary artery disease combined with hyperlipidemia.\n                  <\/jats:p>","DOI":"10.1515\/biol-2025-1223","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:36:39Z","timestamp":1775788599000},"source":"Crossref","is-referenced-by-count":1,"title":["Effects of rosuvastatin and atorvastatin treatment on ET-1, ADMA, and safety efficacy in elderly patients with coronary heart disease combined with hyperlipidemia"],"prefix":"10.1515","volume":"21","author":[{"given":"Ting","family":"Xu","sequence":"first","affiliation":[{"name":"Beijing Tsinghua Changgung Hospital , Beijing , 102218 , China"},{"name":"School of Clinical Medicine , Tsinghua University , Beijing , 102218 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026041002360444873_j_biol-2025-1223_ref_001","doi-asserted-by":"crossref","unstructured":"Hong, SJ, Lee, YJ, Lee, SJ, Hong, BK, Kang, WC, Lee, JY, et al.. Treat-to-target or high-intensity Statin in patients with coronary artery disease: a randomized clinical trial. JAMA 2023;329:1078\u201387. https:\/\/doi.org\/10.1001\/jama.2023.2487.","DOI":"10.1001\/jama.2023.2487"},{"key":"2026041002360444873_j_biol-2025-1223_ref_002","doi-asserted-by":"crossref","unstructured":"Elango, G, Varsha, AP, Bharathi, GM. Impact of side effect management, patient outcomes, and health-care costs in atorvastatin and rosuvastatin therapy: an observational study. Asian J Med Sci 2024;15:23\u20138. https:\/\/doi.org\/10.71152\/ajms.v15i6.3605.","DOI":"10.71152\/ajms.v15i6.3605"},{"key":"2026041002360444873_j_biol-2025-1223_ref_003","doi-asserted-by":"crossref","unstructured":"Honigberg, MC, Zekavat, SM, Aragam, K, Finneran, P, Klarin, D, Bhatt, DL, et al.. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA 2019;322:2411\u201321. https:\/\/doi.org\/10.1001\/jama.2019.19191.","DOI":"10.1001\/jama.2019.19191"},{"key":"2026041002360444873_j_biol-2025-1223_ref_004","doi-asserted-by":"crossref","unstructured":"Chac\u00f3n, JG, Pea, E, Inatti, A. Pharmacokinetics and bioequivalence comparison of two fixed-dose combination of rosuvastatin\/ezetimibe formulations: a randomized, crossover, open-label study in healthy volunteers. J\u00a0Biosci Med 2024;12:119\u201339.","DOI":"10.4236\/jbm.2024.1210012"},{"key":"2026041002360444873_j_biol-2025-1223_ref_005","doi-asserted-by":"crossref","unstructured":"P\u00e9rez de Isla, L, D\u00edaz-D\u00edaz, JL, Romero, MJ, Mu\u00f1iz-Grijalvo, O, Mediavilla, JD, Arg\u00fceso, R, et al.. Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the ARCHITECT study. Circulation 2023;147:1436\u201343. https:\/\/doi.org\/10.1161\/circulationaha.122.062557.","DOI":"10.1161\/CIRCULATIONAHA.122.062557"},{"key":"2026041002360444873_j_biol-2025-1223_ref_006","doi-asserted-by":"crossref","unstructured":"Anagnostis, P, Vaitsi, K, Mintziori, G, Goulis, DG, Mikhailidis, DP. Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia. Curr Med Res Opin 2020;36:731\u201340. https:\/\/doi.org\/10.1080\/03007995.2020.1734783.","DOI":"10.1080\/03007995.2020.1734783"},{"key":"2026041002360444873_j_biol-2025-1223_ref_007","doi-asserted-by":"crossref","unstructured":"Zhao, Q, Wang, L, Kurlansky, PA, Schein, J, Baser, O, Berger, JS. Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study. BMC Cardiovasc Disord 2019;19:19. https:\/\/doi.org\/10.1186\/s12872-018-0991-1.","DOI":"10.1186\/s12872-018-0991-1"},{"key":"2026041002360444873_j_biol-2025-1223_ref_008","unstructured":"EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial hypercholesterolaemia studies collaboration (FHSC). Lancet 2021;398:1713\u201325."},{"key":"2026041002360444873_j_biol-2025-1223_ref_009","doi-asserted-by":"crossref","unstructured":"Liang, YY, Chen, J, Peng, M, Zhou, J, Chen, X, Tan, X, et al.. Association between sleep duration and metabolic syndrome: linear and nonlinear Mendelian randomization analyses. J\u00a0Transl Med 2023;21:90. https:\/\/doi.org\/10.1186\/s12967-023-03920-2.","DOI":"10.1186\/s12967-023-03920-2"},{"key":"2026041002360444873_j_biol-2025-1223_ref_010","doi-asserted-by":"crossref","unstructured":"Taylor, EM, Wu, WW, Ruan, Q, Hall, EC, Giladi, AM, Iorio, ML. Coronary artery disease association with arterial calcifications on routine hand radiographs. J\u00a0Hand Surg Am 2019;44:1060\u20135. https:\/\/doi.org\/10.1016\/j.jhsa.2019.10.004.","DOI":"10.1016\/j.jhsa.2019.10.004"},{"key":"2026041002360444873_j_biol-2025-1223_ref_011","doi-asserted-by":"crossref","unstructured":"Lu, T, Forgetta, V, Yu, OHY, Mokry, L, Gregory, M, Thanassoulis, G, et al.. Polygenic risk for coronary heart disease acts through atherosclerosis in type 2 diabetes. Cardiovasc Diabetol 2020;19:12. https:\/\/doi.org\/10.1186\/s12933-020-0988-9.","DOI":"10.1186\/s12933-020-0988-9"},{"key":"2026041002360444873_j_biol-2025-1223_ref_012","doi-asserted-by":"crossref","unstructured":"Zhou, W, Lee, JCY, Leung, ST, Lai, A, Lee, TF, Chiang, JB, et al.. Long-term prognosis of patients with coronary microvascular disease using stress perfusion cardiac magnetic resonance. JACC Cardiovasc Imaging 2021;14:602\u201311. https:\/\/doi.org\/10.1016\/j.jcmg.2020.09.034.","DOI":"10.1016\/j.jcmg.2020.09.034"},{"key":"2026041002360444873_j_biol-2025-1223_ref_013","doi-asserted-by":"crossref","unstructured":"Egbe, AC, Rihal, CS, Thomas, A, Boler, A, Mehra, N, Andersen, K, et al.. Coronary artery disease in adults with coarctation of aorta: incidence, risk factors, and outcomes. J\u00a0Am Heart Assoc 2019;8:e012056. https:\/\/doi.org\/10.1161\/jaha.119.012056.","DOI":"10.1161\/JAHA.119.012056"},{"key":"2026041002360444873_j_biol-2025-1223_ref_014","unstructured":"Zhang, J, Gong, Y, Peng, J, Han, J, Li, F, Song, L, et al.. Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia. Am J Transl Res 2023;15:3403\u20139."},{"key":"2026041002360444873_j_biol-2025-1223_ref_015","doi-asserted-by":"crossref","unstructured":"Yamashita, S, Arai, H, Bujo, H, Masuda, D, Ohama, T, Ishibashi, T, et al.. Probucol trial for secondary prevention of atherosclerotic events in patients with coronary heart disease (PROSPECTIVE). J\u00a0Atherosclerosis Thromb 2021;28:103\u201323. https:\/\/doi.org\/10.5551\/jat.55327.","DOI":"10.5551\/jat.55327"},{"key":"2026041002360444873_j_biol-2025-1223_ref_016","doi-asserted-by":"crossref","unstructured":"Benlier, N, Erdo\u011fan, MB, Ke\u00e7io\u011flu, S, Orhan, N, \u00c7i\u00e7ek, H. Association of high mobility group box 1 protein with coronary artery disease. Asian Cardiovasc Thorac Ann 2019;27:251\u20135. https:\/\/doi.org\/10.1177\/0218492319835725.","DOI":"10.1177\/0218492319835725"},{"key":"2026041002360444873_j_biol-2025-1223_ref_017","doi-asserted-by":"crossref","unstructured":"Furtado, JD, Ruotolo, G, Nicholls, SJ, Dullea, R, Carvajal-Gonzalez, S, Sacks, FM. Pharmacological inhibition of CETP (cholesteryl ester transfer protein) increases HDL (high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease. Arterioscler Thromb Vasc Biol 2022;42:227\u201337. https:\/\/doi.org\/10.1161\/atvbaha.121.317181.","DOI":"10.1161\/ATVBAHA.121.317181"},{"key":"2026041002360444873_j_biol-2025-1223_ref_018","doi-asserted-by":"crossref","unstructured":"Kokubo, Y, Watanabe, M, Higashiyama, A, Honda-Kohmo, K. Small-dense low-density lipoprotein cholesterol: a subclinical marker for the primary prevention of coronary heart disease. J\u00a0Atherosclerosis Thromb 2020;27:641\u20133. https:\/\/doi.org\/10.5551\/jat.ed134.","DOI":"10.5551\/jat.ED134"},{"key":"2026041002360444873_j_biol-2025-1223_ref_019","doi-asserted-by":"crossref","unstructured":"Bosevski, M, Zlatanovikj, N, Petkoska, D, Gjorgievski, A, Lazarova, E, Stojanovska, L. Plasma homocysteine in patients with coronary and carotid artery disease: a case control study. Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2020;41:15\u201322. https:\/\/doi.org\/10.2478\/prilozi-2020-0019.","DOI":"10.2478\/prilozi-2020-0019"},{"key":"2026041002360444873_j_biol-2025-1223_ref_020","doi-asserted-by":"crossref","unstructured":"Wang, Y, Shen, L, Xu, D. Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease. Clin Cardiol 2019;42:56\u201361. https:\/\/doi.org\/10.1002\/clc.23104.","DOI":"10.1002\/clc.23104"},{"key":"2026041002360444873_j_biol-2025-1223_ref_021","doi-asserted-by":"crossref","unstructured":"Miroshnikova, VV, Panteleeva, AA, Pobozheva, IA, Razgildina, ND, Polyakova, EA, Markov, AV, et al.. ABCA1 and ABCG1 DNA methylation in epicardial adipose tissue of patients with coronary artery disease. BMC Cardiovasc Disord 2021;21:566. https:\/\/doi.org\/10.1186\/s12872-021-02379-7.","DOI":"10.1186\/s12872-021-02379-7"},{"key":"2026041002360444873_j_biol-2025-1223_ref_022","doi-asserted-by":"crossref","unstructured":"Vikulova, DN, Trinder, M, Mancini, GBJ, Pimstone, SN, Brunham, LR. Familial hypercholesterolemia, familial combined hyperlipidemia, and elevated lipoprotein(a) in patients with premature coronary artery disease. Can J Cardiol 2021;37:1733\u201342. https:\/\/doi.org\/10.1016\/j.cjca.2021.08.012.","DOI":"10.1016\/j.cjca.2021.08.012"},{"key":"2026041002360444873_j_biol-2025-1223_ref_023","unstructured":"Tran, AV, Nguyen, KD, Nguyen, KD, Huynh, AT, Tran, BL, Ngo, TH. Predictive performance of CHA2DS2-VASc-HS score and framingham risk scores for coronary disease severity in ischemic heart disease patients with invasive coronary angiography. Eur Rev Med Pharmacol Sci 2023;27:7629\u201336. https:\/\/doi.org\/10.26355\/eurrev_202308_33415."},{"key":"2026041002360444873_j_biol-2025-1223_ref_024","doi-asserted-by":"crossref","unstructured":"Chen, L, Qian, H, Luo, Z, Li, D, Xu, H, Chen, J, et al.. PHACTR1 gene polymorphism with the risk of coronary artery disease in Chinese Han population. Postgrad Med J 2019;95:67\u201371. https:\/\/doi.org\/10.1136\/postgradmedj-2018-136298.","DOI":"10.1136\/postgradmedj-2018-136298"},{"key":"2026041002360444873_j_biol-2025-1223_ref_025","doi-asserted-by":"crossref","unstructured":"Oo, HP, Giovannucci, J, O\u2019Brien, RC, Hare, DL. The prevalence of elevated lipoprotein(a) in patients presenting with coronary artery disease. Heart Lung Circ 2020;29:1682\u20137. https:\/\/doi.org\/10.1016\/j.hlc.2020.03.005.","DOI":"10.1016\/j.hlc.2020.03.005"},{"key":"2026041002360444873_j_biol-2025-1223_ref_026","doi-asserted-by":"crossref","unstructured":"Jamil, S, Jamil, G, Mesameh, H, Qureshi, A, AlKaabi, J, Sharma, C, et al.. Risk factor comparison in young patients presenting with acute coronary syndrome with atherosclerotic coronary artery disease vs. angiographically normal coronaries. Int J Med Sci 2021;18:3526\u201332. https:\/\/doi.org\/10.7150\/ijms.60869.","DOI":"10.7150\/ijms.60869"},{"key":"2026041002360444873_j_biol-2025-1223_ref_027","doi-asserted-by":"crossref","unstructured":"Le\u00f3n-Mimila, P, Villamil-Ram\u00edrez, H, Mac\u00edas-Kauffer, LR, Jacobo-Albavera, L, L\u00f3pez-Contreras, BE, Posadas-S\u00e1nchez, R, et al.. Genome-wide association study identifies a functional SIDT2 variant associated with HDL-C (high-density lipoprotein cholesterol) levels and premature coronary artery disease. Arterioscler Thromb Vasc Biol 2021;41:2494\u2013508. https:\/\/doi.org\/10.1161\/atvbaha.120.315391.","DOI":"10.1161\/ATVBAHA.120.315391"},{"key":"2026041002360444873_j_biol-2025-1223_ref_028","doi-asserted-by":"crossref","unstructured":"Kang, HJ, Kim, MH, Sung, J, Kim, SH, Kim, CH, Park, JE, et al.. Effect of probucol and\/or cilostazol on carotid intima media thickness in patients with coronary heart disease: a randomized, multicenter, multinational study. J\u00a0Atherosclerosis Thromb 2021;28:124\u201336. https:\/\/doi.org\/10.5551\/jat.55616.","DOI":"10.5551\/jat.55616"},{"key":"2026041002360444873_j_biol-2025-1223_ref_029","doi-asserted-by":"crossref","unstructured":"Wang, X, Zhao, J, Wang, H, Zhao, Y, Fu, X. Three-year clinical outcome of unprotected left main coronary artery disease patients complicated with chronic kidney disease treated by coronary artery bypass graft versus percutaneous coronary intervention. Ir J Med Sci 2021;190:89\u201396. https:\/\/doi.org\/10.1007\/s11845-020-02257-9.","DOI":"10.1007\/s11845-020-02257-9"},{"key":"2026041002360444873_j_biol-2025-1223_ref_030","doi-asserted-by":"crossref","unstructured":"Lin, J, Sheng, B, Zhang, X. A mediation analysis of metabolic and inflammatory factors in the severe sleep apnea-coronary heart disease association. Postgrad Med J 2023;100:28\u201335. https:\/\/doi.org\/10.1093\/postmj\/qgad096.","DOI":"10.1093\/postmj\/qgad096"},{"key":"2026041002360444873_j_biol-2025-1223_ref_031","doi-asserted-by":"crossref","unstructured":"Mahdavi-Roshan, M, Mozafarihashjin, M, Shoaibinobarian, N, Ghorbani, Z, Salari, A, Savarrakhsh, A, et al.. Evaluating the use of novel atherogenicity indices and insulin resistance surrogate markers in predicting the risk of coronary artery disease: a case-control investigation with comparison to traditional biomarkers. Lipids Health Dis 2022;21:126. https:\/\/doi.org\/10.1186\/s12944-022-01732-9.","DOI":"10.1186\/s12944-022-01732-9"},{"key":"2026041002360444873_j_biol-2025-1223_ref_032","doi-asserted-by":"crossref","unstructured":"\u00c7aykara, B, Tokat, B, Co\u015fkunp\u0131nar, E, K\u00fc\u00e7\u00fckh\u00fcseyin, \u00d6, Kanca Demirci, D, Bu\u011fra, Z, et al.. Investigation of scavenger receptor class B type I gene variants in patients with coronary heart disease with a history of early myocardial infarction. Turk Kardiyol Dern Ars 2021;49:641\u201353. https:\/\/doi.org\/10.5543\/tkda.2021.08691.","DOI":"10.5543\/tkda.2021.08691"},{"key":"2026041002360444873_j_biol-2025-1223_ref_033","doi-asserted-by":"crossref","unstructured":"Liu, Q, Matthan, NR, Manson, JE, Howard, BV, Tinker, LF, Neuhouser, ML, et al.. Plasma phospholipid fatty acids and coronary heart disease risk: a matched case-control study within the women\u2019s health initiative observational study. Nutrients 2019;11:1672. https:\/\/doi.org\/10.3390\/nu11071672.","DOI":"10.3390\/nu11071672"},{"key":"2026041002360444873_j_biol-2025-1223_ref_034","doi-asserted-by":"crossref","unstructured":"Pedersen, E, Garcia, BH, Halvorsen, KH, Eggen, AE, Schirmer, H, Waaseth, M. Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in troms\u00f8 7. BMC Cardiovasc Disord 2021;21:44. https:\/\/doi.org\/10.1186\/s12872-021-01866-1.","DOI":"10.1186\/s12872-021-01866-1"},{"key":"2026041002360444873_j_biol-2025-1223_ref_035","doi-asserted-by":"crossref","unstructured":"Liu, HH, Cao, YX, Jin, JL, Zhang, HW, Hua, Q, Li, YF, et al.. Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. Heart 2020;106:1228\u201335. https:\/\/doi.org\/10.1136\/heartjnl-2020-316586.","DOI":"10.1136\/heartjnl-2020-316586"},{"key":"2026041002360444873_j_biol-2025-1223_ref_036","doi-asserted-by":"crossref","unstructured":"Poh, KK, Chin, CT, Tong, KL, Tan, JKB, Lim, JS, Yu, W, et al.. Cholesterol goal achievement and lipid-lowering therapy in patients with stable or acute coronary heart disease in Singapore: results from the dyslipidemia international study II. Singapore Med J 2019;60:454\u201362. https:\/\/doi.org\/10.11622\/smedj.2019021.","DOI":"10.11622\/smedj.2019021"},{"key":"2026041002360444873_j_biol-2025-1223_ref_037","unstructured":"Fan, Y, Jin, L, Wu, Y, Fan, Y, Wei, Q. Effects of metoprolol on serum inflammatory factors and myocardial ischemia in rats modeled with coronary heart disease. Am J Transl Res 2021;13:2518\u201327."},{"key":"2026041002360444873_j_biol-2025-1223_ref_038","doi-asserted-by":"crossref","unstructured":"Mir, R, Elfaki, I, Frah, EAM, Alzahrani, KJ, Mir, MM, Banu, S. Clinical correlations of lipid profiles with the age and gender in the coronary artery disease patients: a study of 3878 CAD patients from India. Endocr Metab Immune Disord Drug Targets 2022;22:440\u201352. https:\/\/doi.org\/10.2174\/1871530322666220304110306.","DOI":"10.2174\/1871530322666220304110306"},{"key":"2026041002360444873_j_biol-2025-1223_ref_039","doi-asserted-by":"crossref","unstructured":"Daimon, M, Miyata, H, Motomura, N, Okita, Y, Takamoto, S, Kanki, S, et al.. Outcomes of thoracic aortic surgery in patients with coronary artery disease\u00a0\u2013\u00a0based on the Japan adult cardiovascular surgery database. Circ J 2019;83:978\u201384. https:\/\/doi.org\/10.1253\/circj.cj-18-0703.","DOI":"10.1253\/circj.CJ-18-0703"},{"key":"2026041002360444873_j_biol-2025-1223_ref_040","doi-asserted-by":"crossref","unstructured":"Mahmoud, SES, Shahin, M, Yousif, N, Denegri, A, Abo Dahab, LH, L\u00fcscher, TF. Cardiovascular risk profile, presentation and management outcomes of patients with acute coronary syndromes after coronary artery bypass grafting. Curr Probl Cardiol 2022;47:101078. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.101078.","DOI":"10.1016\/j.cpcardiol.2021.101078"},{"key":"2026041002360444873_j_biol-2025-1223_ref_041","doi-asserted-by":"crossref","unstructured":"Yang, S, Bhatia, N, Xu, M, McPherson, JA. Incidence and predictors of obstructive coronary artery disease and the role of cardiac troponin assays in patients with unstable angina. Tex Heart Inst J 2019;46:161\u20136. https:\/\/doi.org\/10.14503\/thij-17-6329.","DOI":"10.14503\/THIJ-17-6329"},{"key":"2026041002360444873_j_biol-2025-1223_ref_042","doi-asserted-by":"crossref","unstructured":"Arafa, A, Eshak, ES, Iso, H, Shirai, K, Muraki, I, Sawada, N, et al.. Urinary stones and risk of coronary heart disease and stroke: the Japan public health center-based prospective study. J\u00a0Atherosclerosis Thromb 2020;27:1208\u201315. https:\/\/doi.org\/10.5551\/jat.54775.","DOI":"10.5551\/jat.54775"},{"key":"2026041002360444873_j_biol-2025-1223_ref_043","doi-asserted-by":"crossref","unstructured":"Zhang, L, Zhang, S, Yu, Y, Jiang, H, Ge, J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol. Herz 2020;45:594\u2013602. https:\/\/doi.org\/10.1007\/s00059-018-4767-2.","DOI":"10.1007\/s00059-018-4767-2"},{"key":"2026041002360444873_j_biol-2025-1223_ref_044","doi-asserted-by":"crossref","unstructured":"Huang, S, Xie, X, Sun, Y, Zhang, T, Cai, Y, Xu, X, et al.. Development of a nomogram that predicts the risk for coronary atherosclerotic heart disease. Aging (Albany NY) 2020;12:9427\u201339. https:\/\/doi.org\/10.18632\/aging.103216.","DOI":"10.18632\/aging.103216"},{"key":"2026041002360444873_j_biol-2025-1223_ref_045","doi-asserted-by":"crossref","unstructured":"Yoshimura, M, Umemoto, S, Kawano, R, Hiromoto, M, Yamada, M, Fujimura, T, et al.. Non-fasting hypertriglyceridemia as an independent risk factor for coronary in-stent restenosis after primary bare metal stent implantation in patients with coronary artery disease. Int Heart J 2021;62:970\u20139. https:\/\/doi.org\/10.1536\/ihj.21-015.","DOI":"10.1536\/ihj.21-015"},{"key":"2026041002360444873_j_biol-2025-1223_ref_046","doi-asserted-by":"crossref","unstructured":"Li, J, Yang, Y, Jiao, X, Yu, H, Du, Y, Zhang, M, et al.. The clinical role of angiopoietin-like protein 3 in evaluating coronary artery disease in patients with obstructive sleep apnea. Cardiovasc Drugs Ther 2020;34:773\u201380. https:\/\/doi.org\/10.1007\/s10557-020-06991-1.","DOI":"10.1007\/s10557-020-06991-1"},{"key":"2026041002360444873_j_biol-2025-1223_ref_047","doi-asserted-by":"crossref","unstructured":"Benenson, I, Waldron, FA, Jadotte, YT, Dreker, MP, Holly, C. Risk factors for hypertensive crisis in adult patients: a systematic review. JBI Evid Synth 2021;19:1292\u2013327. https:\/\/doi.org\/10.11124\/jbies-20-00243.","DOI":"10.11124\/JBIES-20-00243"},{"key":"2026041002360444873_j_biol-2025-1223_ref_048","doi-asserted-by":"crossref","unstructured":"Ray, KK, Wright, RS, Kallend, D, Koenig, W, Leiter, LA, Raal, FJ, et al.. ORION-10 and ORION-11 investigators. two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N\u00a0Engl J Med 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/nejmoa1912387.","DOI":"10.1056\/NEJMoa1912387"},{"key":"2026041002360444873_j_biol-2025-1223_ref_049","doi-asserted-by":"crossref","unstructured":"\u00d6zdemir, T, \u015eahin, \u0130, Avc\u0131, \u0130\u0130, G\u00fcng\u00f6r, B, Durmaz, E, Tu\u011frul, S, et al.. Assessment of factors related to statin non-adherence in patients with established coronary artery disease: a single-center observational study. Arch Turk Soc Cardiol\/T\u00fcrk Kardiyol Dern Ar\u015f 2017;45:723\u201330. https:\/\/doi.org\/10.5543\/tkda.2017.89947.","DOI":"10.5543\/tkda.2017.89947"},{"key":"2026041002360444873_j_biol-2025-1223_ref_050","doi-asserted-by":"crossref","unstructured":"\u015eayl\u0131k, F, \u00c7\u0131nar, T, Hay\u0131ro\u011flu, M\u0130, Tekke\u015fin, A\u0130. Digital health interventions in patient management following acute coronary syndrome: a meta-analysis of the literature. Anatol J Cardiol 2023;27:2\u20139. https:\/\/doi.org\/10.14744\/anatoljcardiol.2022.2254.","DOI":"10.14744\/AnatolJCardiol.2022.2254"}],"container-title":["Open Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1223\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1223\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:37:06Z","timestamp":1775788626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/biol-2025-1223\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,1,23]]}},"alternative-id":["10.1515\/biol-2025-1223"],"URL":"https:\/\/doi.org\/10.1515\/biol-2025-1223","relation":{},"ISSN":["2391-5412"],"issn-type":[{"value":"2391-5412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"20251223"}}